Full-Time

Logistics and Trade Compliance Director

Confirmed live in the last 24 hours

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Develops treatments for neurological disorders

Compensation Overview

$176.1k - $255.1k/yr

+ Bonus + Equity Incentive Program

Senior, Expert

Company Does Not Provide H1B Sponsorship

San Diego, CA, USA

Category
Supply Chain Management
Transportation & Distribution
Operations & Logistics
Required Skills
Supply Chain Management
Excel/Numbers/Sheets
Requirements
  • BS/BA degree in Business, Supply Chain Management, Logistics, Operations Management, or equivalent and 12+ years of direct domestic and international logistics experience in the biotech / pharmaceutical industry specifically GDP/GMP regulations and Customs/FDA import procedures, as well as demonstrated experience working in logistics including oversight of 3PL’s, freight forwarders and customs brokers, and small package carriers or related experience required; transportation of dangerous goods, and temperature-controlled products including qualification of shipping lanes and containers and launching and distributing new products preferred OR
  • Master's or MBA preferred and 10+ years of experience as noted above
  • Recognized as an internal thought leader with extensive technical and business expertise within a strategic organization
  • Applies in-depth knowledge of own function, business expertise to solve critical issues successfully and innovatively
  • Evaluates key business challenges and completes complex, ambiguous initiatives having cross-functional impact
  • Ability to source vendors, communicate requirements to them, and manage their performance
  • Strong organization, planning, and budget management skills
  • Strong analytical skills, attention to detail, and business process orientation
  • Strong interpersonal and communication skills (written and verbal) and ability to communicate effectively across all levels of the organization with confidence
  • Demonstrated ability to develop effective/collaborative working relationships with cross functional leadership. Ability to understand business requirements, propose solutions, gain alignment, and execute
  • Ability to coordinate and influence the efforts of cross functional teams
  • Ability to prioritize and manage concurrent and, occasionally, competing initiatives in a fast-paced environment. Strong project management skills
  • Ability to work independently as well as part of a team
  • Forward-looking business acumen, with strategic understanding of the broader team impact on the organization
  • Knowledge of direct domestic and international logistics in a biotech / pharmaceutical environment
  • Demonstrated ability to manage logistics including oversight of freight forwarders and customs brokers, and small package carriers
  • Proficient knowledge of GDP/GMP regulations and Customs/FDA import procedures
  • Licensed Customs Broker, preferred
  • Strong knowledge of ERP systems and databases, including Quality Management Systems
  • Proficient knowledge of Microsoft Office and related tools including Excel and Smartsheet
  • Knowledge of transportation of dangerous goods, and temperature-controlled products including qualification of shipping lanes and containers
  • Knowledge of supply chain management and Lean / Six Sigma
  • Knowledge of launching and distributing new products
  • Knowledge of direct domestic and international logistics in a biotech / pharmaceutical environment
Responsibilities
  • Leads, plans and controls the flow of materials, products, services and related systems information from point of origin to point of delivery
  • Directs Global Trade Compliance and related business processes to ensure that all company shipments are conducted in compliance with international regulatory requirements. Includes import-export licensing, shipping lane qualifications, customs declarations, supporting audits of warehouse and distribution centers, shipping/receiving activities, and supporting investigations of product returns and product complaints
  • Assists with the Development and implementation of logistics plans, budgets, and procedures to maximize compliance with customer needs within budget constraints
  • Provides financial reporting of customs duties, freight and storage costs
  • Ensures the secure, reliable and cost-effective delivery of all materials needed to support Neurocrine’s global commercial, clinical, research and development activities, while ensuring compliance with the relevant regulatory requirements and Good Distribution Practices (GDP)
  • Assists with maintenance and publishing of metrics relevant to international logistics
  • Identifies and champions continuous improvement and ensure that corrective actions are implemented for logistics-related deviations or unfavorable performance
  • Provides visibility of shipment status to key stakeholders at Neurocrine
  • Assembles all necessary documents to support international shipments and ensure compliance with global trade requirements
  • Manages shipment schedules and priorities
  • Implements and manages standardized distribution practices and protocols, and related requirements for distribution centers, carriers, and related partners
  • Accurately maintains logistics and inventory related transactions in the system of record; researches and corrects data errors as necessary
  • Partners with cross-functional teams for the selection, qualification, implementation, and management of service providers, shipping lanes, and shipping containers
  • Optimizes global logistics spend through analysis of shipping lanes, volumes, and activities
  • Understands and communicates current and updated US and foreign requirements for customs documentation and reporting
  • Supports the development and management of standardized practices for the importation and exportation of materials for Neurocrine globally
  • Provides leadership of logistics and trade compliance activities across Neurocrine
  • Ensures Good Distribution Practices are met at all times
  • Other duties as assigned
Desired Qualifications
  • Licensed Customs Broker, preferred
Neurocrine Biosciences

Neurocrine Biosciences

View

Neurocrine Biosciences focuses on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company has a range of FDA-approved medications for conditions such as tardive dyskinesia, Huntington's disease-related chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids. Their products work by targeting specific pathways in the brain and body to alleviate symptoms associated with these disorders. What sets Neurocrine apart from its competitors is its deep understanding of the connections between brain and body systems, which informs their research and development efforts. The company's goal is to relieve suffering for patients with unmet medical needs by providing effective treatments for complex conditions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • Neurocrine's CRENESSITY shows promising results in treating congenital adrenal hyperplasia.
  • The company is expanding its pipeline with Phase 3 trials for schizophrenia treatment.
  • Neurocrine's share repurchase program reflects strong financial health and investor confidence.

What critics are saying

  • Increased competition in congenital adrenal hyperplasia treatments may impact market share.
  • The Phase 3 trial of NBI-1117568 poses financial risks if unsuccessful.
  • Strategic shifts from new CIO may disrupt ongoing IT projects.

What makes Neurocrine Biosciences unique

  • Neurocrine focuses on targeted treatments for neurological and neuroendocrine disorders.
  • The company has a diverse portfolio including therapies for rare diseases.
  • Neurocrine's strategic collaborations enhance its drug development capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Parental Leave

Health Insurance

Dental Insurance

Vision Insurance

Paid Holidays

Company News

Cache Valley Daily
Jun 9th, 2025
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer

SAN DIEGO, June 9, 2025 /PRNewswire/ - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025.

GlobeNewswire
Jun 2nd, 2025
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568

Tokyo, Japan and Cambridge, UK, 3 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine...

PR Newswire
May 15th, 2025
Neurocrine Biosciences Presents Data On Improvements In Physiologic Glucocorticoid Dosing And Select Reproductive Hormones In Patients With Classic Congenital Adrenal Hyperplasia Taking Crenessity™ (Crinecerfont)

90% of Pediatric Participants on CRENESSITY versus 21% on Placebo Achieved ≥1 Threshold for Androstenedione Reduction or Glucocorticoid Reduction. Observed Rates of Select Reproductive Hormone Normalization in Adult Males Taking CRENESSITY with Substantial Glucocorticoid Dose Reductions. Findings Presented at the 2025 American Association of Clinical Endocrinology Annual MeetingSAN DIEGO, May 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies of CRENESSITY™ (crinecerfont). The data showed that a substantial proportion of pediatric patients with classic congenital adrenal hyperplasia achieved physiologic-range glucocorticoid doses and normal androstenedione levels. Additionally, adult male patients with classic congenital adrenal hyperplasia observed improvements in select reproductive hormone levels. Both adult and pediatric patients achieved substantial reductions in glucocorticoid doses. These results were presented at the 2025 American Association of Clinical Endocrinology Annual Meeting in Orlando

PR Newswire
May 14th, 2025
Neurocrine Biosciences Presents Findings Contributing To The Growing Body Of Evidence On The Impact Of High-Dose Glucocorticoids On Clinical Outcomes In Congenital Adrenal Hyperplasia

Most Studies Meeting the Literature Review Criteria Found That a Higher Glucocorticoid Dose was Statistically Significantly Associated with Adverse Clinical OutcomesFindings Presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research Annual MeetingSAN DIEGO, May 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented today a systematic literature review illustrating the relationship between higher glucocorticoid dose and adverse clinical outcomes, including decreased bone mineral density, increased insulin resistance and higher body mass index, in patients with congenital adrenal hyperplasia. This study was presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting in Montreal, Canada.Congenital adrenal hyperplasia (CAH) is a rare, lifelong genetic condition linked to overproduction of adrenal androgens and cortisol deficiency. CAH is traditionally treated with lifelong high-dose glucocorticoids (GCs), which increase the risk of complications across multiple aspects of health. However, the relationship between GC dose and adverse clinical outcomes in CAH has not been fully explored. This systematic literature review was conducted to analyze the relationship between GC dose and clinical outcomes, and is the first to capture the impact of higher GC dose on the incidence and severity of all relevant adverse clinical outcomes in patients with CAH."CAH requires lifelong glucocorticoid therapy to manage adrenal androgen excess and cortisol deficiency, but high doses often lead to significant complications, including cardiometabolic, bone and growth issues," said Eiry W

Clinical Trial Vanguard
May 1st, 2025
Neurocrine Starts Phase 3 Trial of NBI-1117568 for Schizophrenia

Nxera Pharma's partner, Neurocrine Biosciences, has launched a Phase 3 trial for NBI-1117568, an oral M4 selective receptor agonist, for schizophrenia treatment.